Beck Bode LLC’s Agilon Health AGL Stock Holding History

Beck Bode LLC’s Portfolio AGL Stock Details AGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,801	Closed	-$4.04M	–	135
2023 Q1	$4.04M	Buy	+6,801	New	+$3.81M	0.99%	34

Other funds holding AGL

CDR

Clayton Dubilier & Rice New York $536M AUM 0.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Beck Bode LLC's AGL Position: Q2 2023 in Review

Beck Bode LLC sold out of Agilon Health (AGL) in Q2 2023, closing a stake of 6,801 shares — an estimated $4.04M sold.

Beck Bode LLC first reported a position in AGL in Q1 2023 and held it in 1 quarter. The position peaked at $4.04M in Q1 2023. 185 funds tracked by Wall St. Rank hold AGL as of Q2 2023.

Beck Bode LLC reported no remaining Agilon Health position as of Q2 2023 after selling out during the quarter.
Beck Bode LLC sold 6,801 Agilon Health shares in Q2 2023, an estimated $4.04M.
Beck Bode LLC first reported a position in Agilon Health in Q1 2023 and held it in 1 quarter.
Beck Bode LLC's Agilon Health position peaked at $4.04M in Q1 2023.
185 funds tracked by Wall St. Rank held Agilon Health as of Q2 2023.

Based on Beck Bode LLC's 13F filing for Q2 2023, filed 10 Aug 2023.